- Telehealth Visits
- Insurance plan information
Paul L. Nadler, MD
Internal Medicine • Urgent CareDirector, UCSF Screening and Acute Care Clinic- Telehealth Visits
- Insurance plan information
Urgent Care Parnassus
Paul L. Nadler, MD
Internal Medicine • Urgent CareDirector, UCSF Screening and Acute Care ClinicUrgent Care Parnassus
- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Paul Nadler is a specialist in internal medicine and medical director of the UCSF Screening and Acute Care Clinic. He has extensive experience in outpatient urgent care.
One focus of Nadler's research is new technologies to improve the quality of urgent care. He also studies how to better manage orthopedic problems in primary care.
Nadler earned his medical degree at the State University of New York School of Medicine. He completed a residency in internal medicine at the University of California, Davis Medical Center.
Education & training
Board certification
- Internal Medicine, American Board of Internal Medicine
Residency
- Internal Medicine, University of California Davis
Internship
- Internal Medicine, University of California Davis
Degree
- MD, State University of New York (SUNY) at Buffalo
My expertise
Specialties
Locations
My research
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.